PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molmedLink to Publisher's site
 
Mol Med. 1996 November; 2(6): 665–669.
PMCID: PMC2230137

The role of candidate genes in the etiology of schizophrenia.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (818K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Moises HW, Gelernter J, Giuffra LA, Zarcone V, Wetterberg L, Civelli O, Kidd KK, Cavalli-Sforza LL, Grandy DK, Kennedy JL, et al. No linkage between D2 dopamine receptor gene region and schizophrenia. Arch Gen Psychiatry. 1991 Jul;48(7):643–647. [PubMed]
  • Shaikh S, Gill M, Owen M, Asherson P, McGuffin P, Nanko S, Murray RM, Collier DA. Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am J Med Genet. 1994 Mar 15;54(1):8–11. [PubMed]
  • Buckland PR, O'Donovan MC, McGuffin P. Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 1992;106(4):479–483. [PubMed]
  • Buckland PR, O'Donovan MC, McGuffin P. Clozapine and sulpiride up-regulate dopamine D3 receptor mRNA levels. Neuropharmacology. 1993 Sep;32(9):901–907. [PubMed]
  • Coon H, Byerley W, Holik J, Hoff M, Myles-Worsley M, Lannfelt L, Sokoloff P, Schwartz JC, Waldo M, Freedman R, et al. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am J Hum Genet. 1993 Feb;52(2):327–334. [PubMed]
  • Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet. 1992 Dec;29(12):858–860. [PMC free article] [PubMed]
  • Schaid DJ, Sommer SS. Comparison of statistics for candidate-gene association studies using cases and parents. Am J Hum Genet. 1994 Aug;55(2):402–409. [PubMed]
  • Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ. Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet. 1994 Mar 15;54(1):21–26. [PubMed]
  • Asherson P, Mant R, Holmans P, Williams J, Cardno A, Murphy K, Jones L, Collier D, McGuffin P, Owen MJ. Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Mol Psychiatry. 1996 May;1(2):125–132. [PubMed]
  • Ravindranathan A, Coon H, DeLisi L, Holik J, Hoff M, Brown A, Shields G, Crow T, Byerley W. Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatr Genet. 1994 Summer;4(2):77–80. [PubMed]
  • Kalsi G, Sherrington R, Mankoo BS, Brynjolfsson J, Sigmundsson T, Curtis D, Read T, Murphy P, Butler R, Petursson H, et al. Linkage study of the D5 dopamine receptor gene (DRD5) in multiplex Icelandic and English schizophrenia pedigrees. Am J Psychiatry. 1996 Jan;153(1):107–109. [PubMed]
  • Scambler PJ, Kelly D, Lindsay E, Williamson R, Goldberg R, Shprintzen R, Wilson DI, Goodship JA, Cross IE, Burn J. Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus. Lancet. 1992 May 9;339(8802):1138–1139. [PubMed]
  • Kelly D, Goldberg R, Wilson D, Lindsay E, Carey A, Goodship J, Burn J, Cross I, Shprintzen RJ, Scambler PJ. Confirmation that the velo-cardio-facial syndrome is associated with haplo-insufficiency of genes at chromosome 22q11. Am J Med Genet. 1993 Feb 1;45(3):308–312. [PubMed]
  • Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet. 1992 Jan 1;42(1):141–142. [PubMed]
  • Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, Morrow B, Karayiorgou M, Antonarakis SE, Housman D, et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis. 1994 Aug;182(8):476–478. [PubMed]
  • Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry. 1972 Apr;128(10):1310–1312. [PubMed]
  • Poitou P, Assicot M, Bohuon C. Soluble and membrane catechol-o-methyl transferases in red blood cells of schizophrenic patients. Biomedicine. 1974 Feb;21(2):91–93. [PubMed]
  • White HL, McLeod MN, Davidson JR. Catechol O-methyltransferase in red blood cells of schizophrenic, depressed, and normal human subjects. Br J Psychiatry. 1976 Feb;128:184–187. [PubMed]
  • Floderus Y, Ross SB, Wetterberg L. Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin Genet. 1981 May;19(5):389–392. [PubMed]
  • Lewander T, von Pongracz G, Bäckström M, Wetterberg L. Dopamine metabolism in red blood cells in schizophrenia. Clin Genet. 1981 May;19(5):410–413. [PubMed]
  • Baron M, Gruen R, Levitt M, Hunter C, Asnis L. Erythrocyte catechol O-methyltransferase activity in schizophrenia: analysis of family data. Am J Psychiatry. 1984 Jan;141(1):29–32. [PubMed]
  • Eberhard G, Ross S, Säf J, Wahlund B, Wetterberg L. Psychoses in twins. A 10 year clinical and biochemical follow-up study. Schizophr Res. 1989 Jul-Oct;2(4-5):367–374. [PubMed]
  • Daniels JK, Williams NM, Williams J, Jones LA, Cardno AG, Murphy KC, Spurlock G, Riley B, Scambler P, Asherson P, et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry. 1996 Feb;153(2):268–270. [PubMed]
  • Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995 Jul 29;346(8970):281–282. [PubMed]
  • Hallmayer J, Kennedy JL, Wetterberg L, Sjögren B, Kidd KK, Cavalli-Sforza LL. Exclusion of linkage between the serotonin2 receptor and schizophrenia in a large Swedish kindred. Arch Gen Psychiatry. 1992 Mar;49(3):216–219. [PubMed]
  • Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet. 1996 May 11;347(9011):1294–1296. [PubMed]
  • Malhotra AK, Goldman D, Buchanan R, Breier A, Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996 Jun 29;347(9018):1830–1831. [PubMed]
  • Jönsson E, Nöthen MM, Bunzel R, Propping P, Sedvall G. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996 Jun 29;347(9018):1831–1831. [PubMed]
  • Arranz MJ, Lin MW, Powell J, Kerwin R, Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996 Jun 29;347(9018):1831–1832. [PubMed]
  • Sasaki T, Hattori M, Fukuda R, Kunugi H, Nanko S. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996 Jun 29;347(9018):1832–1832. [PubMed]
  • WOOLF B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955 Jun;19(4):251–253. [PubMed]
  • Burnet PW, Harrison PJ. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet. 1995 Sep 30;346(8979):909–909. [PubMed]
  • Nöthen MM, Rietschel M, Erdmann J, Oberländer H, Möller HJ, Nober D, Propping P. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet. 1995 Sep 30;346(8979):908–909. [PubMed]
  • Asherson P, Walsh C, Williams J, Sargeant M, Taylor C, Clements A, Gill M, Owen M, McGuffin P. Imprinting and anticipation. Are they relevant to genetic studies of schizophrenia? Br J Psychiatry. 1994 May;164(5):619–624. [PubMed]
  • Bassett AS, Honer WG. Evidence for anticipation in schizophrenia. Am J Hum Genet. 1994 May;54(5):864–870. [PubMed]
  • Thibaut F, Martinez M, Petit M, Jay M, Campion D. Further evidence for anticipation in schizophrenia. Psychiatry Res. 1995 Nov 29;59(1-2):25–33. [PubMed]
  • O'Donovan MC, Guy C, Craddock N, Murphy KC, Cardno AG, Jones LA, Owen MJ, McGuffin P. Expanded CAG repeats in schizophrenia and bipolar disorder. Nat Genet. 1995 Aug;10(4):380–381. [PubMed]
  • Morris AG, Gaitonde E, McKenna PJ, Mollon JD, Hunt DM. CAG repeat expansions and schizophrenia: association with disease in females and with early age-at-onset. Hum Mol Genet. 1995 Oct;4(10):1957–1961. [PubMed]
  • Cardno AG, Murphy KC, Jones LA, Guy CA, Asherson P, De Azevedo MH, Coelho IM, de Macedo e Santos AJ, Pato CN, McGuffin P, et al. Expanded CAG/CTG repeats in schizophrenia. A study of clinical correlates. Br J Psychiatry. 1996 Dec;169(6):766–771. [PubMed]
  • Bowen T, Guy C, Speight G, Jones L, Cardno A, Murphy K, McGuffin P, Owen MJ, O'Donovan MC. Expansion of 50 CAG/CTG repeats excluded in schizophrenia by application of a highly efficient approach using repeat expansion detection and a PCR screening set. Am J Hum Genet. 1996 Oct;59(4):912–917. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ